sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Position on Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its interest in Avadel Pharmaceuticals plc as per Irish Takeover Panel Rules. As of November 26, 2025, Vanguard holds 5,577,577 US$0.01 ordinary shares, representing 5.73% of Avadel's relevant securities. This establishes Vanguard as a significant stakeholder, as the disclosure threshold is 1% or more of the company's shares.
During recent transactions, Vanguard purchased 1,306 shares and sold 537 shares, both at $21.40 per share. No cash-settled derivatives or stock-settled derivatives, such as options relating to Avadel, have been reported by Vanguard. Additionally, the company states that there are no indemnity or option arrangements concerning Avadel shares.
This position disclosure reflects Vanguard's compliance with regulatory requirements, while providing insight into their stake in Avadel Pharmaceuticals.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.